The UK enters 2026 with something its market has not had for four years: fiscal predictability. The Bank of England’s base rate settled at 3.75% at the close of 2025, and mortgage products have re-priced into a range the market can actually transact in. Savills has revised its UK real-estate total-return forecast to 7.8% per annum for 2026 through 2030. The wait-and-see posture of 2024 has closed. What comes next, in our view, is a transactional recovery led by recapitalisations rather than fresh deployments.
Normalised growth, uneven geography
National house-price growth is expected to sit in a 2% to 4% band, per Nationwide and Halifax. The striking feature of that forecast is not the number — it is the dispersion around it. London and the South East sit at the lower end, around 1.3% to 2% for Greater London, priced by high entry levels and tighter rent control. The North-South differential is narrowing. Manchester, Leeds and Birmingham are running hotter, supported by relative affordability, regeneration pipelines and institutional interest in BTR stock.
The buyer mix has also shifted. First-time-buyer activity is at its highest share in more than a decade, an indicator that the market is now being driven by affordability fundamentals rather than speculative capital. Wage growth has finally caught up with — and in some segments overtaken — house-price inflation. That is a healthier base than the 2021 peak.
Build-to-Rent as the residential default
The institutional residential story in the UK is now structurally BTR. Private landlords continue to exit under the weight of the Renters’ Rights Act, which banned no-fault evictions and capped deposits. The void is filling with professional operators. Our expectation is that 2026 sees a material recovery in the BTR development pipeline, as housebuilders with slower sales-market velocities look for more predictable forward-funded exits.
The sharper trade, in our view, is existing stabilised stock. Yield on acquisition is lower than development, but the risk profile is significantly tighter, and rental growth on stabilised BTR is expected to remain above long-run averages on the back of chronic supply shortage in prime locations. For equity providers, the interesting structures are recapitalisations of first-generation BTR vehicles where original LP commitments are drawing down and operators need growth capital to add to existing platforms.
Commercial: selective recognition
Offices in prime central locations are re-entering institutional favour. The scarcity of high-specification, ESG-compliant London CBD space pushed prime rents into double-digit growth territory in late 2025. That trajectory looks durable. What is not durable is any secondary or peripheral office asset with an EPC below C — those are the assets generating the refinancing pipeline rather than the leasing demand.
Industrial remains robust. On-shoring of supply chains and a national focus on energy-resilient warehousing are sustaining occupational demand. Vacancies in the Golden Triangle are at historic lows, and modern, power-ready space is commanding a clear premium. As borrowing costs drift toward 3%, the yield spread to gilts remains healthy enough to make UK industrial one of the cleaner risk-adjusted trades in developed markets.
The recapitalisation pipeline
Our primary focus for UK deployments in 2026 is the refinancing wall. A significant volume of loans originated in the 2019–2021 low-rate era comes due in the first half. Even on stabilised assets, stricter LTV covenants mean borrowers need fresh equity simply to hold position. For well-capitalised counterparties, that is a pipeline of quality stock available through recap rather than open-market auction — typically on better economics than a competitive bid would yield.
Sale-and-leaseback volumes are also climbing as UK corporates look to release balance-sheet equity for operational expansion. That creates long-dated, high-covenant income in mission-critical locations — a structure that pairs well with our mandate’s duration profile.
M24 perspective. The UK is a market where active management and disciplined structuring matter more than directional calls. The headline return forecast is healthy, but the alpha is in accessing recapitalisations at sensible entry points, funding the ESG retrofit that unlocks the “green premium,” and holding the position through the next rate-compression cycle. The window for patient equity is open. We expect it to narrow as global institutional capital rotates back into the region.